Radioenhancing Hafnium Oxide Nanoparticles (NBTXR3) Followed by Stereotactic Body Radiation Therapy in Patients With Hepatocellular Carcinoma and Liver Metastases (NBTXR3-103): Phase 1 Dose-Escalation Trial.

Date publication

janvier 2026

Journal

Advances in radiation oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre , Pr PEIFFERT Didier

Tous les auteurs :
Chajon E, Pracht M, Rolland Y, Nguyen F, Bronowicki JP, Durand-Labrunie J, Vendrely V, Cunha AS, Laurent V, Rio E, Sourd SL, Gustin P, Said PC, Dimitriu M, Facer BD, Vivar OI, Peiffert D, Deutsch E, de Baère T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41438485

Résumé

Stereotactic body radiation therapy (SBRT) is a common treatment for unresectable liver cancers; however, delivering ablative doses while minimizing normal tissue toxicity is challenging. NBTXR3, a novel radioenhancer, demonstrated enhanced radiation therapy (RT) efficacy with minimal toxicity in healthy tissue. We evaluated NBTXR3 intratumoral injection followed by SBRT for hepatocellular carcinoma (HCC) or liver metastases.

Référence

Adv Radiat Oncol. 2026 01;11(1):101937